Summary
All nitrovasodilators act intracellularly by a common molecular mechanism. This is characterized by the release of nitric oxide (NO). They are, thus, prodrugs or carriers of the active principle NO, responsible for endothelial controlled vasodilation. The rate of NO-formation strongly correlates with the activation of the soluble guanylate cyclase in vitro, resulting in a stimulation of cGMP synthesis. Nitrovasodilators thus are therapeutic substitutes for endogenous EDRF/NO. The pathways of bioactivation, nevertheless, differ substantially, depending on the individual chemistry of the nitrovasodilator. Besides NO, numerous other reaction products such as nitrite and nitrate anions are formed. The guanylate cyclase is only activated if NO is liberated. In the case of organic nitrates such as GTN, NO is only formed if certain thiol compounds are present as an essential cofactor. The rate of NO-formation correlates with the number of nitrate ester groups and proceeds with a simultaneous nitrite formation (with a ratio of 1: 14 in the presence of cysteine). Nitrosamines such as molsidomine do not need thiol compounds for bioactivation. They directly liberate NO from the ring-open A-forms. This process basically depends on the presence of oxygen as electron acceptor from the sydnonimine molecule. Therefore, besides NO also Superoxide radicals are formed, which may react with the generated NO under formation of nitrate ions. Organic nitrites (such as amyl nitrite) require the preceding interaction with a mercapto group to form a S-nitrosothiol intermediate, from which finally NO radicals are liberated. Nitrosothiols (like S-nitroso-acetyl-penicillamine) and sodium nitroprusside spontaneously release NO. The molecules themselves do not possess a direct enzyme activating potency. In the presence of thiol compounds organic nitrites (e. g., amyl nitrite) and nitrosothiols may act as intermediary products of NO generation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abdollah A, Moffat JA, Armstrong PW (1987) N-acetylcysteine does not modify nitroglycerin-induced tolerance in canine vascular rings. J Cardiovasc Pharmacol 9:445–450
Bohn H, Schönafinger K (1989) Oxygen and oxidation promote the release of nitric oxide from sydnonimines. J Cardiovasc Pharmacol 14 (Suppl 11):S6–S12
Cooke JP, Andon N, DelDuca D, Dzau V, Loscalzo J (1989) S-nitrosocaptopril: a novel vasodilator resistant to nitrate tolerance. Circulation 80 (Suppl) II–559
Crandall LA (1932) The fate of glyceryl trinitrate in the tolerant and non-tolerant animal. J Pharmacol Exptl Therapeut 48:127–140
Doyle MP, Hoekstra JW (1981) Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem 14:351–358
Feelisch M (1988) Experimentelle Untersuchungen zum intrazellulären Wirkungsmechanismus der Nitrovasodilatatoren und der endothelabhängigen Gefaßregulation. Beweis für die Bildung von Stickoxid (NO) als gemeinsamem, intermediärem Wirkungsvermittler. Thesis, Düsseldorf
Feelisch M, Noack (1987) Molecular prerequisites of thiol-containing compounds like cysteine for their stimulatory action on the degradation of organic nitrates and activation of soluble guanylate cyclase. N S Arch Pharmacol 335 Suppl:46
Feelisch M, Noack E (1987) Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 139:19–30
Feelisch M, Noack E (1987) Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. Eur J Pharmacol 142:465–469
Feelisch M, Ostrowski J, Noack E (1989) On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 14 (Suppl. 11):S13–S22
Gruetter CA, Lemke SM (1986) Effects of sulfhydryl reagents on nitroglycerin-induce relaxation of bovine coronary artery. Can J Physiol Pharmacol 64:1395–1401
Haussmann HJ, Werringloer J (1985) Nitric oxide and nitrite formation during the degradation of N-nitrosamines. Nauny-Schmiedeberg’s Arch Pharmacol 329 (Suppl R21):84
Henry PJ, Horowitz JD, Louis WJ (1989) Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. J Pharmacol Exp Ther 248:762–768
Ignarro LJ, Kadowitz PJ, Baricos WH (1981) Evidence that regulation of hepatic guanylate cyclase activity involves interactions between catalytic site SH-groups and both substrate and activator. Arch Biochem Biophys 208:75–86
May DC, Popma JJ, Black WH, Schaefer S, Lee HR, Levine BD, Hillis LD (1987) In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 317:805–809
Moffat JA, Armstrong PW, Marks GS (1982) Investigations into the role of sulfhydryl groups in the mechanism of action of the nitrates. Can J Physiol Pharmacol 60:1261–1266
Needleman P, Krantz JC (1965) The biotransformation of nitroglycerin. Biochem Pharmacol 14:1225–1230
Newman CM, Warren JB, Taylor GW, Boobis AR, Davies DS (1990) Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: prevention by N-acetyl-l-but not N-acetyl-d-cysteine. Br J Pharmacol 99:825–829
Noack E (1984) Investigations on structure-activity relationship in organic nitrates. Meth and Find Exptl Clin Pharmacol 6:583–586
Noack E (1990) Mechanisms of nitrate tolerance — influence of the metabolic activation pathways. Z Kardiol 79:Suppl 2
Noack E, Feelisch M (1989) Molecular aspects underlying the vasodilator action of molsidomine. J Cardiovasc Pharmacol 14 (Suppl 11):S1–S5
Noack E, Schröder H, Feelisch M (1986) Continuous determination of nitric oxide formation during non-enzymatic degradation of organic nitrates and its correlation to guanylate cyclase activation. N S Arch Pharmacol 332 Suppl:125–00
Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M (1987) Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 317:799–804
Schröder H, Noack E (1986) Neue Ergebnisse zur thiolabhängigen Aktivierung der Guanylatcyklase durch organische Nitrate. Z Kardiol 75, Suppl 3:20–24
Schröder H, Noack E (1987) Structure-activity relationship of organic nitrates for activation of guanylate cyclase. Arch int pharmacodyn Ther 290:225–246
Schröder H, Noack E, Müller R (1985) Evidence for a correlation between nitric oxide formation by cleavage of organic nitrates and activation of guanylate cyclase. J Mol Cell Cardiol 17:931–934
Servent D, Delaforge M, Ducrocq C, Mansuy D, Lenfant M (1989) Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: involvement of cytochrome P-450. Biochem Biophys Res Commun 163:1210–1216
Taylor T, Taylor IW, Chasseaud LF, Bonn R (1987) Pharmacokinetics and metabolism of organic nitrate vasodilators. Progress in Drug metabolism 10:207–336
Torresi J, Horowitz JD, Dusting GJ (1985) Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine. J Cardiovasc Pharmacol 7:777–783
Wolf J, Werringloer J (1988) Metabolic degradation of glyceryl trinitrate. N S Arch Pharmacol 337 (Suppl):34
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Noack, E., Feelisch, M. (1991). Molecular mechanisms of nitrovasodilator bioactivation. In: Drexler, H., Zeiher, A.M., Bassenge, E., Just, H. (eds) Endothelial Mechanisms of Vasomotor Control. Steinkopff. https://doi.org/10.1007/978-3-642-72461-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-72461-9_5
Publisher Name: Steinkopff
Print ISBN: 978-3-642-72463-3
Online ISBN: 978-3-642-72461-9
eBook Packages: Springer Book Archive